{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:19:54Z","timestamp":1773670794935,"version":"3.50.1"},"reference-count":54,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T00:00:00Z","timestamp":1408924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Lung cancer (LC) and colorectal cancer (CRC) are the first and second deadliest types of cancer worldwide. EGFR-based therapy has been used in the treatment of these cancers with variable success. Presence of mutations in the KRAS driver oncogene, possibly induced by environmental factors such as carcinogens in diet and cigarette smoke, may confer worse prognosis and resistance to treatment for reasons not fully understood. Data on possible associations between KRAS mutational status and clinical and metabolic parameters, which may help in clinical management, as well as in identifying risk factors for developing these cancers, are limited in the current literature. We sequenced the KRAS gene and investigated the associations of variations in 108 patients with non-small cell lung carcinoma (NSCLC), the most common form of LC, and in 116 patients with CRC.  All of the mutations originated from the guanosine nucleotide and over half of all transversions in NSCLC and CRC were c.34 G&gt;T and c.35 G&gt;T, respectively.  c.35 G&gt;A was the most frequent type of transition in both cancers. Excluding smoking, the clinical and metabolic parameters in patients carrying mutant and wild type KRAS were similar except that the CRC patients with transversion mutations were 8.6 years younger than those carrying the transitions (P &lt; 0.01). Dyslipidemia, hypertension, family cancer history, and age of diagnosis older than 60 years were more frequent in NSCLC than CRC (P \u2264 0.04). These results suggest that most of the clinical and metabolic parameters investigated in this study are probably not associated with the more aggressive phenotype and differences in response to EGFR-based treatment previously reported in patients with KRAS mutations. However, the increased rates of abnormal metabolic parameters in patients with NSCLC in comparison to CRC indicate that these parameters may be more important in the management of NSCLC. CRC patients carrying transition mutations are older than those carrying transversions, suggesting that age may determine the type of KRAS mutation in CRC patients.<\/jats:p>","DOI":"10.3390\/ijerph110908645","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T11:58:03Z","timestamp":1408967883000},"page":"8645-8660","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations"],"prefix":"10.3390","volume":"11","author":[{"given":"Ahmet","family":"Yilmaz","sequence":"first","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehad","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Shilo","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Villalona-Calero","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Animal Sciences, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Frankel","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Otterson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2014,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1055-9965.EPI-06-0144","article-title":"Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics","volume":"15","author":"Einspahr","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_3","first-page":"1315","article-title":"Molecularly targeted drugs for metastatic colorectal cancer","volume":"7","author":"Cheng","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2217\/pgs.13.177","article-title":"EGFR and KRAS mutations, and ALKfusions: Current developments and personalized therapies for patients with advanced non-small-cell lung cancer","volume":"14","author":"Madureira","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1513\/pats.200809-107LC","article-title":"KRAS mutations in non-small cell lung cancer","volume":"6","author":"Riely","year":"2009","journal-title":"Proc. Amer. Thorac. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/onc.2012.88","article-title":"Oncogenic KRAS and BRAF activation of the MEK\/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4\/MKP2) resulting in nuclear ERK1\/2 inhibition","volume":"32","author":"Cagnol","year":"2013","journal-title":"Oncogene"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/(SICI)1096-9896(200003)190:4<423::AID-PATH540>3.0.CO;2-T","article-title":"Ki-ras activation in vitro affects G1 and G2M cell-cycle transit times and apoptosis","volume":"190","author":"Orecchia","year":"2000","journal-title":"J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ctrv.2008.11.005","article-title":"Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR","volume":"35","author":"Heinemann","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clcc.2013.04.005","article-title":"Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing","volume":"12","author":"Stover","year":"2013","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#","article-title":"K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung","volume":"72","author":"Westra","year":"1993","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/carcin\/bgt290","article-title":"Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC","volume":"34","author":"Gilsing","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Slagter, S.N., Vliet-Ostaptchouk, J.V., Vonk, J.M., Boezen, H.M., Dullaart, R.P., Kobold, A.C., Feskens, E.J., van Beek, A.P., van der Klauw, M.M., and Wolffenbuttel, B.H. (2013). Associations between smoking, components of metabolic syndrome and lipoprotein particle size. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-195"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2012.48.5201","article-title":"Maintenance therapy for advanced lung cancer: Who, what, and when?","volume":"31","author":"Gerber","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dom\u00e9nech, E., G\u00f3mez-L\u00f3pez, G., Gzlez-Pe\u00f1a, D., L\u00f3pez, M., Herreros, B., Menezes, J., G\u00f3mez-Lozano, N., Carro, A., Gra\u00f1a, O., and Pisano, D.G. (2012). New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. PLoS One, 7.","DOI":"10.1371\/journal.pone.0038158"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/modpathol.2010.220","article-title":"Genetic aberrations in primary esophageal melanomas: Molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases","volume":"24","author":"Langer","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000167864","article-title":"The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract","volume":"79","author":"Oki","year":"2009","journal-title":"Digestion"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_19","first-page":"4689","article-title":"Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis","volume":"61","author":"Esteller","year":"2001","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jnci\/dji275","article-title":"MGMT promoter methylation and field defect in sporadic colorectal cancer","volume":"97","author":"Shen","year":"2005","journal-title":"J. Natl. Cancer. Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/annonc\/mdf226","article-title":"Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype","volume":"13","author":"Bazan","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_22","first-page":"1","article-title":"K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers\u2014A review","volume":"24","author":"Minamoto","year":"2000","journal-title":"Cancer Detect. Prev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.0.CO;2-A","article-title":"A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients","volume":"69","author":"Span","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.prp.2007.06.001","article-title":"K-ras mutation detection in colorectal cancer using the Pyrosequencing technique","volume":"203","author":"Poehlmann","year":"2007","journal-title":"Pathol. Res. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/1055-9965.EPI-13-0090","article-title":"Second Manifestations of ARTerial Disease (SMART) Study Group. Cancer risk in patients with manifest vascular disease: Effects of smoking, obesity, and metabolic syndrome","volume":"22","author":"Peeters","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_27","first-page":"595","article-title":"Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas","volume":"41","author":"Gao","year":"2012","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4067\/S0034-98872013000900009","article-title":"KRAS gene mutation in colorectal cancer","volume":"141","author":"Roa","year":"2013","journal-title":"Rev. Med. Chil."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.6061\/clinics\/2012(05)03","article-title":"Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients","volume":"67","author":"Bacchi","year":"2012","journal-title":"Clinics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/CBM-2012-0233","article-title":"Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer","volume":"10","author":"Xu","year":"2012","journal-title":"Cancer Biomark."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00018013","article-title":"EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: Patient outcome, interplay with morphology and immunophenotype","volume":"43","author":"Warth","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: A comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"Li","year":"2014","journal-title":"Brit. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3892\/ol.2013.1551","article-title":"Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers","volume":"6","author":"Takamochi","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Raparia, K., Villa, C., Raj, R., and Cagle, P.T. (2014). Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura. Arch. Pathol. Lab. Med., in press.","DOI":"10.5858\/arpa.2013-0759-OA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000357812","article-title":"Analysis of KRAS mutations in cases of metastatic colorectal cancer at a single institution in Tochigi, Japan","volume":"81","author":"Saito","year":"2014","journal-title":"Pathobiology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ferreira, C.G., Aran, V., Zalcberg-Renault, I., Victorino, A.P., Salem, J.H., Bonamino, M.H., Vieira, F.M., and Zalis, M. (2014). KRAS mutations: Variable incidences in a Brazilian cohort of 8234 metastatic colorectal cancer patients. BMC Gastroenterol., 14.","DOI":"10.1186\/1471-230X-14-73"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.ejca.2014.04.001","article-title":"Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy","volume":"50","author":"Cserepes","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mrgentox.2007.12.008","article-title":"Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: Results from the Netherlands Cohort Study","volume":"652","author":"Weijenberg","year":"2008","journal-title":"Mutat. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/ajg.2012.21","article-title":"Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women","volume":"107","author":"Samadder","year":"2012","journal-title":"Amer. J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12094-011-0712-z","article-title":"APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: Results of a cross-sectional study","volume":"9","author":"Martinez","year":"2011","journal-title":"Clin. Transl. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sinha, R., Hussain, S., Mehrotra, R., Kumar, R.S., Kumar, K., Pande, P., Doval, D.C., Basir, S.F., and Bharadwaj, M. (2013). Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: Indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS One.","DOI":"10.1371\/journal.pone.0060142"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3748\/wjg.v19.i32.5286","article-title":"Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia","volume":"19","author":"Aissi","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.lungcan.2009.02.025","article-title":"Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: Its implication in carcinogenesis","volume":"66","author":"Okudela","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mrfmmm.2004.02.011","article-title":"Hypermethylation of the DNA repair gene MGMT: Association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors","volume":"554","author":"Bello","year":"2004","journal-title":"Mutat. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S2576","DOI":"10.1093\/jn\/137.11.2576S","article-title":"Dietary modulation of colon cancer risk","volume":"137","author":"Kim","year":"2007","journal-title":"J. Nutr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.lungcan.2013.11.010","article-title":"KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies","volume":"83","author":"Maus","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.metabol.2011.06.020","article-title":"The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients","volume":"61","author":"Lee","year":"2012","journal-title":"Metabolism"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/CEJ.0b013e3283240460","article-title":"Impact of metabolic factors on subsequent cancer risk: Results from a large-scale population-based cohort study in Japan","volume":"18","author":"Inoue","year":"2009","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1055-9965.EPI-06-0391","article-title":"Metabolic abnormalities and risk for colorectal cancer in the physicians\u2019 health study","volume":"15","author":"Sturmer","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10552-009-9428-6","article-title":"Metabolic syndrome components and colorectal adenoma in the CLUE II cohort","volume":"21","author":"Tsilidis","year":"2010","journal-title":"Cancer Causes Control"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/cncr.27923","article-title":"Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients","volume":"119","author":"Yang","year":"2013","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mrrev.2009.07.003","article-title":"Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: Etiopathogenic similarities, differences and paradoxes","volume":"682","author":"Porta","year":"2009","journal-title":"Mutat. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bruera, G., Cannita, K., di Giacomo, D., Lamy, A., Fr\u00e9bourg, T., Sabourin, J.C., Tosi, M., Alesse, E., Ficorella, C., and Ricevuto, E. (2013). Worse prognosis of KRAS c.35 G>A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B\/FOx). BMC Med., 11.","DOI":"10.1186\/1741-7015-11-59"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/11\/9\/8645\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:15:10Z","timestamp":1760217310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/11\/9\/8645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,25]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9]]}},"alternative-id":["ijerph110908645"],"URL":"https:\/\/doi.org\/10.3390\/ijerph110908645","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,25]]}}}